HAEMONETICS CORPORATION (HAE) FY2027 Q1 P&L / Income Statement

HAEMONETICS CORPORATION (HAE) FY2027 Q1 P&L / Income Statement

Income statement for 2026-03-29 through 2026-06-27. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenues

339,380,000 US dollars

Cost of goods sold

136,577,000 US dollars

Gross profit

202,803,000 US dollars

Total operating expenses

145,345,000 US dollars

Operating income

57,458,000 US dollars

Other income (expense), net (calculated)

negative 9,884,000 US dollars

Income before provision for income taxes

47,574,000 US dollars

Provision for income taxes

14,564,000 US dollars

Net income

33,010,000 US dollars

Apheresis - Plasma

155,524,000 US dollars

Apheresis - Other

35,794,000 US dollars

MedSurg - Blood Management Technologies

88,120,000 US dollars

MedSurg - Interventional Technologies

59,942,000 US dollars

Research and development

16,200,000 US dollars

Selling, general and administrative

118,941,000 US dollars

Amortization of acquired assets

10,204,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.